keyword
MENU ▼
Read by QxMD icon Read
search

Febuxostat

keyword
https://www.readbyqxmd.com/read/28631197/prioritizing-future-research-on-allopurinol-and-febuxostat-for-the-management-of-gout-value-of-information-analysis
#1
Eric Jutkowitz, Fernando Alarid-Escudero, Hyon K Choi, Karen M Kuntz, Hawre Jalal
OBJECTIVES: The aim of this study was to quantify the value of conducting additional research and reducing uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout. METHODS: We used a previously developed Markov model that evaluated the cost effectiveness of nine urate-lowering strategies: no treatment, allopurinol-only fixed dose (300 mg), allopurinol-only dose escalation (up to 800 mg), febuxostat-only fixed dose (80 mg), febuxostat-only dose escalation (up to 120 mg), allopurinol-febuxostat sequential therapy fixed dose, allopurinol-febuxostat sequential therapy dose escalation, febuxostat-allopurinol sequential therapy fixed dose, and febuxostat-allopurinol sequential therapy dose escalation...
June 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28597604/lesinurad-a-selective-uric-acid-reabsorption-inhibitor-in-combination-with-febuxostat-in-patients-with-tophaceous-gout-a-phase-iii-clinical-trial
#2
Nicola Dalbeth, Graeme Jones, Robert Terkeltaub, Dinesh Khanna, Jeff Kopicko, Nihar Bhakta, Scott Adler, Maple Fung, Chris Storgard, Scott Baumgartner, Fernando Perez-Ruiz
OBJECTIVE: Investigate efficacy and safety of lesinurad in combination with febuxostat in patients with tophaceous gout in a 12-month, phase III trial. METHODS: Patients with serum urate (sUA) ≥8.0 mg/dl (≥6.0 mg/dl on urate-lowering therapy) and ≥1 measurable target tophus were given febuxostat 80mg daily for 3 weeks before randomization to lesinurad (200 or 400mg daily) or placebo added to febuxostat. Primary endpoint was proportion of patients achieving sUA <5...
June 9, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28584186/comparative-effectiveness-of-allopurinol-versus-febuxostat-for-preventing-incident-renal-disease-in-older-adults-an-analysis-of-medicare-claims-data
#3
Jasvinder A Singh, John D Cleveland
OBJECTIVE: To assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in elderly. METHODS: In a retrospective cohort study using 2006-2012 Medicare claims data, we included patients newly treated with allopurinol or febuxostat (baseline period of 183 days without either medication). We used 5:1 propensity-matched Cox regression analyses to compare the HR of incident renal disease with allopurinol use (and dose) versus febuxostat (reference)...
June 5, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28578274/synthesis-and-characterization-of-a-novel-organic-nitrate-ndhp-role-of-xanthine-oxidoreductase-mediated-nitric-oxide-formation
#4
Zhengbing Zhuge, Luciano L Paulo, Arghavan Jahandideh, Maria C R Brandão, Petrônio F Athayde-Filho, Jon O Lundberg, Valdir A Braga, Mattias Carlström, Marcelo F Montenegro
In this report, we describe the synthesis and characterization of 1,3-bis(hexyloxy)propan-2-yl nitrate (NDHP), a novel organic mono nitrate. Using purified xanthine oxidoreductase (XOR), chemiluminescence and electron paramagnetic resonance (EPR) spectroscopy, we found that XOR catalyzes nitric oxide (NO) generation from NDHP under anaerobic conditions, and that thiols are not involved or required in this process. Further mechanistic studies revealed that NDHP could be reduced to NO at both the FAD and the molybdenum sites of XOR, but that the FAD site required an unoccupied molybdenum site...
May 26, 2017: Redox Biology
https://www.readbyqxmd.com/read/28566603/febuxostat-for-the-prevention-of-recurrent-2-8-dihydroxyadenine-nephropathy-due-to-adenine-phosphoribosyltransferase-deficiency-following-kidney-transplantation
#5
Koji Nanmoku, Akira Kurosawa, Takahiro Shinzato, Toshihiro Shimizu, Takaaki Kimura, Takashi Yagisawa
Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder that results in irreversible renal damage due to 2,8-dihydroxyadenine (DHA) nephropathy. A 28-year-old man underwent living-related kidney transplantation for chronic kidney disease of unknown etiology. Numerous spherical brownish crystals observed in his urinary sediment on postoperative day 3 and were observed within the tubular lumen of renal allograft biopsy specimens on postoperative day 7. After a genetic diagnosis, febuxostat treatment was started on postoperative day 7, with the dosage gradually increased to 80 mg/day until complete the disappearance of 2,8-DHA crystals...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28544467/a-survey-on-the-beliefs-and-knowledge-of-gout-management-in-new-medical-graduates-new-south-wales-australia
#6
Matthew Terrill, John Riordan
AIM: To assess the beliefs and knowledge of gout management in new medical graduates. METHOD: A survey on gout management was sent to new medical graduates during their orientation week, New South Wales, Australia. RESULTS: Of 15 hospital networks, 11 agreed to participate. From these, 168 graduates responded (23.7% response rate). Most (81.1%) felt that gout was a serious disease, 51.2% answered that they had been taught adequately to manage acute gout, only 37...
May 25, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28532636/erratum-regarding-febuxostat-in-hyperuricemic-patients-with-advanced-ckd-am-j-kidney-dis-2016-68-5-819-821
#7
(no author information available yet)
No abstract text is available yet for this article.
June 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28521802/identification-of-chronic-kidney-disease-patient-characteristics-influencing-the-renoprotective-effects-of-febuxostat-therapy-a-retrospective-follow-up-study
#8
Akinori Yamaguchi, Makoto Harada, Yosuke Yamada, Koji Hashimoto, Yuji Kamijo
BACKGROUND: The ability of antihyperuricemic therapy to exert renoprotective effects in patients with chronic kidney disease (CKD) is controversial. In the present study, we studied patient characteristics that may mask favorable impact of antihyperuricemic therapy on the progression of CKD. METHODS: This was a single-center, retrospective, follow-up study. One-hundred and seventy-eight CKD patients with hyperuricemia who received febuxostat therapy were included in this study...
May 18, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28503330/febuxostat-attenuates-renal-damage-besides-exerting-hypouricemic-effect-in-streptozotocin-induced-diabetic-rats
#9
Jianmin Ran, Gang Xu, Huixuan Ma, Hailing Xu, Yan Liu, Rongshao Tan, Ping Zhu, Jun Song, Gancheng Lao
Aim. In this study, we aimed to investigate the effects of febuxostat, a novel inhibitor of xanthine oxidase (XO), on renal damage in streptozotocin- (STZ-) induced diabetic rats. Methods. Diabetes was induced by the intraperitoneal injection of STZ in male Sprague-Dawley rats. Sham-injected rats served as controls. The control and diabetic rats were treated with and without febuxostat for 8 weeks, respectively. Fasting blood and 24-h urine samples were collected every 4 weeks. Rat livers were extracted for detecting gene expression, content, and bioactivity of XO...
2017: International Journal of Nephrology
https://www.readbyqxmd.com/read/28485997/prophylaxis-of-acute-flares-when-initiating-febuxostat-for-chronic-gouty-arthritis-in-a-real-world-clinical-setting
#10
Jinquan Yu, Qian Qiu, Liuqin Liang, Xiuyan Yang, Hanshi Xu
OBJECTIVE: Flare prophylaxis is recommended during urate-lowering therapy (ULT) despite lack of proven benefit especially when initiating febuxostat. We investigated if colchicine or steroids administration during initiation of febuxostat for chronic gouty arthritis reduces the frequency and/or severity of acute gout flares. METHODS: Patients with confirmed diagnosis of gout starting febuxostat were retrospectively studied. Frequency, severity, and length of flares were analyzed...
May 9, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28463849/effect-of-febuxostat-on-the-endothelial-dysfunction-in-hemodialysis-patients-a-randomized-placebo-controlled-double-blinded-study
#11
Mona Alshahawey, Sara Mahmoud Shahin, Tamer Wahid Elsaid, Nagwa Ali Sabri
BACKGROUND: Endothelial dysfunction is an important risk factor for cardiovascular diseases to occur in end-stage renal disease patients. Febuxostat, being a novel xanthine oxidase inhibitor, is apparently having a beneficial role in improving the endothelial dysfunction; however, data among hemodialysis patients are still limited. METHODS: A prospective, placebo-controlled, block-randomized, double-blinded study was carried out to evaluate the effect of oral febuxostat on the endothelial dysfunction in hemodialysis patients...
2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/28460508/-effect-of-febuxostat-on-epithelial-to-mesenchymal-transition-of-kidney-tubules-serum-interleukin-6-and-transforming-growth-factor-%C3%AE-1-in-hyperuricemic-rats
#12
Z M Lin, R S Zhang, C X Fan, Y L Liang, L Li, L Zhao, J C Qu, X Xu, H Y Zhao, X N Liu, K S Zhu
Objective: To observe the effect of febuxostat on epithelial-to-mesenchymal transition (EMT) of kidney tubules and the levels of serum IL-6 nad transforming growth factor (TGF)β(1) in hyperuricemic rats. Methods: Forty male SD rats were divided into 4 groups: normal control group (NC group), oteracil potassium group (OP group), oteracil potassium with febuxostat group (OF group) and oteracil potassium with benzbromarone group (OB group). Each group had 10 rats and balanced in body weights. To induce hyperuricemia, rats were given oteracil potassium by gastric gavage once a day for eight weeks...
May 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28458354/previous-dosage-of-allopurinol-is-a-strong-determinant-of-febuxostat-efficacy
#13
Hiroyoshi Koide, Daiki Hira, Masayuki Tsujimoto, Yurie Katsube, Tetsuya Minegaki, Takashi Uzu, Yoshito Ikeda, Shin-Ya Morita, Kohshi Nishiguchi, Tomohiro Terada
Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective investigation, was carried out to analyze the effects of patient characteristics on the efficacy of febuxostat. A total of 225 patients who were continuously prescribed the same dose of febuxostat for 8-12 weeks from the initial therapy were enrolled in the present study...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28455534/xanthine-oxidase-inhibition-by-febuxostat-attenuates-stress-induced-hyperuricemia-glucose-dysmetabolism-and-prothrombotic-state-in-mice
#14
Maimaiti Yisireyili, Motoharu Hayashi, Hongxian Wu, Yasuhiro Uchida, Koji Yamamoto, Ryosuke Kikuchi, Mohammad Shoaib Hamrah, Takayuki Nakayama, Xian Wu Cheng, Tadashi Matsushita, Shigeo Nakamura, Toshimitsu Niwa, Toyoaki Murohara, Kyosuke Takeshita
Chronic stress is closely linked to the metabolic syndrome, diabetes, hyperuricemia and thromboembolism, but the mechanisms remain elusive. We reported recently that stress targets visceral adipose tissue (VAT), inducing lipolysis, low-grade inflammation with production of inflammatory adipokines, metabolic derangements such as insulin resistance, and prothrombotic state. In the present study, we hypothesized the involvement of VAT xanthine oxidoreductase (XOR), a source of reactive oxygen species (ROS) and uric acid (UA) in the above processes...
April 28, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28430170/current-management-of-gout-practical-messages-from-2016-eular-guidelines
#15
George Nuki, Michael Doherty, Pascal Richette
The European League Against Rheumatism published updated recommendations for the management of gout in 2016, comprising 3 overarching principles and 11 key recommendations for clinical practice. Patient education about the pathophysiology of gout and its comorbidities, as well as the existence of effective treatments are important, and understanding the principles of managing acute attacks and eliminating urate crystals by lifelong lowering of the serum urate (SU) below a target level are essential. Advice about lifestyle, diet, weight, and other risk factors, as well as the need to screen for, and manage, comorbidities is emphasized...
April 28, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28425024/lesinurad-a-review-in-hyperuricaemia-of-gout
#16
Emma D Deeks
Lesinurad (Zurampic(®)) is an oral selective inhibitor of the URAT1 and OAT4 uric acid (UA) transporters of the kidney, via which it inhibits UA reabsorption and thus increases renal UA excretion and lowers serum UA (sUA) levels. Lesinurad 200 mg once daily is indicated for use in combination with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in adults with gout who have not achieved target sUA levels with an XOI alone. Approval was based on three 12-month phase 3 trials that evaluated lesinurad in combination with allopurinol in adults with gout inadequately responsive to allopurinol (CLEAR 1 and 2) and in combination with febuxostat in adults with tophaceous gout (CRYSTAL)...
April 19, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28408434/renal-and-vascular-effects-of-uric-acid-lowering-in-normouricemic-patients-with-uncomplicated-type-1-diabetes
#17
Yuliya Lytvyn, Ronnie Har, Amy Locke, Vesta Lai, Derek Fong, Andrew Advani, Bruce A Perkins, David Z I Cherney
Higher plasma uric acid (PUA) levels are associated with lower GFR and higher blood pressure (BP) in patients with type 1 diabetes (T1D). Our aim was to determine the impact of PUA lowering on renal and vascular function in patients with uncomplicated T1D.T1D patients (n=49) were studied under eu- and hyperglycemic conditions at baseline and after PUA lowering with febuxostat (FBX) for 8 weeks. Healthy controls (HC) were studied under normoglycemic conditions (n=24). PUA, GFR (inulin), effective renal plasma flow (ERPF, paraaminohippurate), BP and hemodynamic responses to an infusion of angiotensin II (assessment of intrarenal RAAS) were measured pre- and post-FBX...
April 13, 2017: Diabetes
https://www.readbyqxmd.com/read/28379501/cardiovascular-effects-of-urate-lowering-therapies-in-patients-with-chronic-gout-a-systematic-review-and-meta-analysis
#18
Tony Zhang, Janet E Pope
Objectives.: To determine if urate-lowering treatment (ULT) in gout can reduce cardiovascular (CV) outcomes. Methods.: Randomized trials were searched for treatment with ULT in gout. Eligible trials had to report CV safety of a ULT. Potential medications included allopurinol, febuxostat, pegloticase, rasburicase, probenecid, benzbromarone, sulphinpyrazone, losartan, fenofibrate and sodium-glucose linked transporter 2 inhibitors. Results.: A total of 3084 citations were found, with 642 duplicates...
March 30, 2017: Rheumatology
https://www.readbyqxmd.com/read/28365572/cost-effectiveness-analysis-for-genotyping-before-allopurinol-treatment-to-prevent-severe-cutaneous-adverse-drug-reactions
#19
Ching-Hua Ke, Wen-Hung Chung, Yen-Hsia Wen, Yaw-Bin Huang, Hung-Yi Chuang, You-Lin Tain, Yu-Ching Lily Wang, Cheng-Chih Wu, Chien-Ning Hsu
OBJECTIVE: Patients with an HLA-B*58:01 allele have an increased risk of developing severe cutaneous adverse drug reactions (SCAR) when treated with allopurinol. Although one-off pharmacogenetic testing may prevent life-threatening adverse drug reactions, testing prior to allopurinol initiation incurs additional costs. The study objective was to evaluate the cost-effectiveness of HLA-B*58:01 screening compared with using other available urate-lowering agents (ULA). METHODS: A decision-analytical model was used to compare direct medical costs and effectiveness [including lifetime saved, quality-adjusted life-yrs (QALY) gained] in treating new patients with the following options: (1) genetic screening followed by allopurinol prescribing for noncarriers of HLAB* 58:01, (2) prescribing benzbromarone without screening, (3) prescribing febuxostat without screening, and (4) prescribing allopurinol without screening...
April 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28335813/tumor-lysis-syndrome-in-an-extraskeletal-osteosarcoma-a-case-report-and-review-of-the-literature
#20
Vito Emanuele Catania, Michele Vecchio, Michele Malaguarnera, Roberto Madeddu, Giulia Malaguarnera, Saverio Latteri
BACKGROUND: This case report describes a spontaneous tumor lysis syndrome due to a rare solid tumor. CASE PRESENTATION: A 65-year-old white woman had tumor lysis syndrome, which represent a dangerous oncological emergency. This syndrome occurs usually with a hematological tumor, but in this case our patient had a solid tumor, which was a rare extraskeletal osteosarcoma, localized in her pelvic region. She also had lung metastases and bilateral hydronephrosis. After spontaneous tumor lysis syndrome, she had acute renal insufficiency, which was treated with hemodialysis and successively with rasburicase, Kayexalate (sodium polystyrene sulfonate), and febuxostat...
March 24, 2017: Journal of Medical Case Reports
keyword
keyword
8954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"